BzATP triethylammonium salt

Name: BzATP triethylammonium salt
Brand: MedChemExpress
SKU: HY-136254
Rating: 5.0 (14 reviews)

Cat. No.: HY-136254 Purity: 99.19%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively. BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively.

For research use only. We do not sell to patients.

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 14 publication(s) in Google Scholar

Other Forms of BzATP triethylammonium salt:

BzATP triethylammonium Get quote

14 Publications Citing Use of MCE BzATP triethylammonium salt

In Vivo Efficacy Study

ELISA

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jan 30:e2412556. [Abstract]; Drawing of ELISA technique for the detection of inflammatory cytokines secreted by BzATP (BzATP triethylammonium salt)‐activated cultured microglia (left). The concentration of IL‐6 released by microglia after BzATP (100 μM) treatment for 0 h, 4 h, 12 h, 24 h, and 36 h (right). Two‐way ANOVA. n = 4.

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: Neurobiol Dis. 2025 Jan 28:106817. [Abstract]; Cell culture exposure to 500 nM S100A9 (prepared by protocol III) for 24 h was followed by 3 mM BzATP (BzATP triethylammonium salt) treatment for 1 h.

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: CNS Neurosci Ther. 2025 Nov;31(11):e70668. [Abstract]; Representative traces showing the effect of injections of saline and BzATP (BzATP triethylammonium salt, 100 μM, 80 nL per injection) on PND activity.

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 30;25(17):9411. [Abstract]; Cells were treated by RPMI1640, LPC (100 μg/mL), LPC + Q (25 μmol/L), or LPC + Q + BzATP (BzATP triethylammonium salt, 100 µmol/L) for 3 h. Representative immunoblots probed for H3cit, P38MAPK, p-P38MAPK, NOX2, MPO, P2X7R, and β-Actin are shown.

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 30;25(17):9411. [Abstract]; BzATP (BzATP triethylammonium salt, 100 µmol/L; 3 h). The level of NETs marker MPO-DNA in the supernatant was detected by ELISA.

: BzATP triethylammonium salt purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Aug 30;25(17):9411. [Abstract]; BzATP (BzATP triethylammonium salt, 100 µmol/L; 3 h). The formation of NETs was identified by labeling with H3cit and observed by fluorescence microscopy (scale bar, 50 µm).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All P2X Receptor Isoform Specific Products:

View All Isoforms

P2X1 Receptor P2X2 Receptor P2X3 Receptor P2X4 Receptor P2X7 Receptor

Biological Activity
Purity & Documentation
References
Customer Review

Description

BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively^[1]. BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively^[2].

IC₅₀ & Target

p2x1 Receptor

P2X3 Receptor

P2X4 Receptor

P2X7 Receptor

In Vitro

BzATP (10-1000 μM; 24 h) promotes the proliferation and migration of U87 and U251 glioma cells^[3].
P2X7R protein expression is induced by BzATP (100 μM; 6-48 h) in human glioma cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:	U87 and U251 glioma cells
Concentration:	5, 10, 50, 100, 500 and 1000 μM
Incubation Time:	2, 6, 12, 24, 48 and 72 hours
Result:	The proliferation of U87 and U251 glioma cell lines was significantly increased in the presence of 10-1000 uM and 100-1000 μM, respectively. The peak of cell proliferation of both U87 and U251 cell lines was at 100 μM. The optimal incubation time is 24 hours in both U87 and U251 cells lines.

Western Blot Analysis^[3]

Cell Line:	U87 and U251 glioma cells
Concentration:	100 μM
Incubation Time:	6-48 hours
Result:	Induced the upregulation of P2X7R.

In Vivo

BzATP (5 mg/kg) significantly promotes P2X7R expression in the intestines compared with intestines in the sham group and the control group after cecal ligation and puncture (CLP) induction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male 2-month-old C57BL/6 mice (each weighing between 20 and 25 g)^[4]
Dosage:	5 mg/kg
Administration:	Injected through the intraperitoneal route
Result:	At 48 hours, mice in the treated group and control group exhibited mortalities of 91% and 86%, respectively.

Molecular Weight

1018.97

Formula

C₂₄H₂₄N₅O₁₅P₃.C₁₈H₄₅N₃

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@H](O[C@H]([C@@H]1OC(C(C=C2)=CC=C2C(C3=CC=CC=C3)=O)=O)N4C5=NC=NC(N)=C5N=C4)COP(OP(OP([O-])(O)=O)([O-])=O)([O-])=O.O=C(O[C@@H]6[C@H](O[C@H]([C@@H]6O)N7C8=NC=NC(N)=C8N=C7)COP(OP(OP([O-])(O)=O)([O-])=O)([O-])=O)C(C=C9)=CC=C9C(C%10=CC=CC=C%10)=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O : 50 mg/mL (49.07 mM; Need ultrasonic)

DMSO : 25 mg/mL (24.53 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9814 mL	4.9069 mL	9.8138 mL
5 mM	0.1963 mL	0.9814 mL	1.9628 mL
10 mM	0.0981 mL	0.4907 mL	0.9814 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.19%

Select Batch:

Data Sheet (283 KB) SDS (252 KB)

COA (255 KB) HNMR (501 KB) RP-HPLC (211 KB) MS (74 KB)

Handling Instructions (2659 KB)

References

[1]. B R Bianchi, et al. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur J Pharmacol. 1999 Jul 2;376(1-2):127-38. [Content Brief]

[2]. Mark T Young, et al. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2007 Jan;71(1):92-100. [Content Brief]

[3]. Zhenhua Ji, et al. Involvement of P2X 7 Receptor in Proliferation and Migration of Human Glioma Cells. Biomed Res Int. 2018 Jan 9;2018:8591397. [Content Brief]

[4]. Xiuwen Wu, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Sci Rep. 2017 Jun 29;7(1):4364. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	0.9814 mL	4.9069 mL	9.8138 mL	24.5346 mL
	5 mM	0.1963 mL	0.9814 mL	1.9628 mL	4.9069 mL
	10 mM	0.0981 mL	0.4907 mL	0.9814 mL	2.4535 mL
	15 mM	0.0654 mL	0.3271 mL	0.6543 mL	1.6356 mL
	20 mM	0.0491 mL	0.2453 mL	0.4907 mL	1.2267 mL
H₂O	25 mM	0.0393 mL	0.1963 mL	0.3926 mL	0.9814 mL
	30 mM	0.0327 mL	0.1636 mL	0.3271 mL	0.8178 mL
	40 mM	0.0245 mL	0.1227 mL	0.2453 mL	0.6134 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.